| Literature DB >> 12815486 |
F Yoshiba1, M Hagihara, K Tazume, Y Ogawa, K Kishi, A Higuchi, S Kato, T Hotta.
Abstract
A patient with chronic active Epstein-Barr virus (EBV) infection was treated by allogeneic SCT from an HLA-identical sibling donor, using a nonmyeloablative regimen. Even on day 70, mixed chimerism remained together with a quite high viral load. On days 76 and 90, donor lymphocytes were infused after short-term culture with OKT3 plus recombinant IL-2. At 8 days after the last dose, all hematopoietic cells were shown to be donor-type dominant; thereafter, the viral load started to decrease and finally disappeared. Anti-mHA-specific CTLs were generated in vitro, which were shown to be effective in eradicate viral-infected recipient T lymphocytes.Entities:
Mesh:
Year: 2003 PMID: 12815486 DOI: 10.1038/sj.bmt.1704074
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483